PinkDx Tests Vaginal Swab for Endometrial Cancer

The new diagnostic tool aims to replace invasive biopsies for women experiencing abnormal uterine bleeding.

Updated on Oct. 30, 2026 in Cancer

PinkDx Tests Vaginal Swab for Endometrial Cancer

Live Poll

Do you trust new non-invasive testing methods more than traditional invasive diagnostic procedures?

PinkDx is developing a non-invasive vaginal swab test designed to identify endometrial cancer by analyzing genetic material shed from the uterine lining. The diagnostic aims to provide a more comfortable alternative to traditional uterine biopsies.

Why it matters

Traditional endometrial biopsies can be painful and fail to collect sufficient tissue in many postmenopausal patients. This new test could improve cancer screening access by simplifying the diagnostic process for women with abnormal bleeding.

The study currently involves 3,000 women across 16 U.S. sites, a significant increase from an early pilot test involving 27 patients. The new test targets a 90% cancer detection rate and a 50% rule-out rate for those without the disease.

The players

PinkDx

PinkDx is a California-based diagnostic company currently developing non-invasive genomic screening tools for gynecological cancers.

The details

Clinicians collect genetic material shed from the uterus using a simple swab, which laboratories then analyze for specific tumor fingerprints. This method specifically targets cancer cells that originate in the uterine lining.

The current clinical study is expected to conclude in 2026.
PinkDx expects to complete CMS certification by early 2027.
The company plans to offer the test to patients by mid-2027.

The Big Picture

This development represents a major shift away from the standard endometrial biopsy procedure that has long served as the primary diagnostic benchmark. The test signals a move toward liquid-biopsy-style screenings that utilize genetic material to improve diagnostic accuracy.

The test aims to spare women from the discomfort and high failure rate of traditional invasive uterine biopsies. It potentially offers a more accessible screening option for those experiencing abnormal bleeding, simplifying the diagnostic routine.

The takeaway

This innovation highlights the growing role of genetic material in non-invasive cancer screenings. Women experiencing abnormal bleeding should continue to consult their healthcare providers about currently available biopsy options while awaiting further clinical results.

What happens next

The ongoing clinical study involving 3,000 participants is scheduled to conclude in 2026, followed by a targeted CMS certification process in early 2027.